Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
LLY compared with TBPH: revenue, margins and what each company keeps, and the suppliers and customers both name
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
TBPH
Theravance Biopharma, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
LLY
ELI Lilly & Co
vs
TBPH
Theravance Biopharma, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
TBPH: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only LLY
29
MCK
McKesson
customer
CAH
Cardinal Health
customer
VEEV
Veeva Systems
supplier
UTHR
United Therapeutics
customer
25 more · LLY chain
›
Shared
0
No shared counterparties.
Only TBPH
6
VTRS
Viatris
supplier
LAZ
Lazard
supplier
GSK
GSK
customer
RPRX
Royalty Pharma Investments
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
2 more · TBPH chain
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
LLY, solid
TBPH, dashed
LLY
ELI Lilly & Co
Change
1,417.89
▲
+0.60%
· post 1,419.27
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
TBPH
Theravance Biopharma, Inc.
Change
17.03
▲
+0.02%
· post 17.04
Closed
Nov 4 '26
Mkt cap
$884.2M
Revenue
$21M
Q2 FY26
Revenue
$107M
FY25
vs
Compare
Closed
Nov 4 '26
LLY
ELI Lilly & Co
vs
TBPH
Theravance Biopharma, Inc.
1,417.89
▲
+0.60%
post 1,419.27
Price
17.03
▲
+0.02%
post 17.04
$1.3T
Mkt cap
$884.2M
Q3 FY26
$24.4B
Revenue
$21M
Q2 FY26
FY25
$65.2B
Revenue
$107M
FY25
Change
Change
LLY
1,417.89
▲
+0.60%
vs
TBPH
17.03
▲
+0.02%
Closed
Nov 4 '26